PAAMCP
ESPR

Pacific Alternative Asset Management Company (PAAMCO)’s Esperion Therapeutics ESPR Stock Holding History

Pacific Alternative Asset Management Company (PAAMCO)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,600
Closed -$889K – 51
2015
Q1 		$889K Buy
+9,600
New +$620K 0.24% 59

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacific Alternative Asset Management Company (PAAMCO)'s ESPR Position: Q3 2014 in Review

Pacific Alternative Asset Management Company (PAAMCO) sold out of Esperion Therapeutics (ESPR) in Q3 2014, closing a stake of 12,444 shares — an estimated $197K sold.

Pacific Alternative Asset Management Company (PAAMCO) first reported a position in ESPR in Q1 2014 and held it in 2 quarters. The position peaked at $310K in Q1 2014. 50 funds tracked by Wall St. Rank hold ESPR as of Q3 2014.

  • Pacific Alternative Asset Management Company (PAAMCO) reported no remaining Esperion Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Pacific Alternative Asset Management Company (PAAMCO) sold 12,444 Esperion Therapeutics shares in Q3 2014, an estimated $197K.
  • Pacific Alternative Asset Management Company (PAAMCO) first reported a position in Esperion Therapeutics in Q1 2014 and held it in 2 quarters.
  • Pacific Alternative Asset Management Company (PAAMCO)'s Esperion Therapeutics position peaked at $310K in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2014.

Based on Pacific Alternative Asset Management Company (PAAMCO)'s 13F filing for Q3 2014, filed 13 Nov 2014.